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ABSTRACT We investigated the expression of metabotropic glutamate receptors
(mGluR) in the prefrontal cortex (PFC) and striatum in schizophrenia. mGluRs modu-
late the release and reuptake of synaptic glutamate and mediate some molecular cor-
relates of neuroplasticity, including long-term potentiation. The mGluRs are expressed
widely in the PFC and striatum, regions often implicated in the pathophysiology of
schizophrenia. Thus, we hypothesized that abnormal expression of mGluRs might con-
tribute to glutamatergic dysfunction observed in the PFC and striatum in schizophre-
nia. Accordingly, we measured the expression of metabotropic glutamate receptors
(mGluRs) in Brodmann areas 9, 11, 32, and 46 in the prefrontal cortex (PFC) and the
caudate, putamen, and nucleus accumbens in schizophrenia (16 cases, 9 controls) by
Western blot analysis. We found an increase in the expression of mGluR1a and
mGluR2/3 immunoreactivity in the PFC in schizophrenia, while no changes in the
expression of mGluR4a or mGluR5 were detected in this region. In the striatum we
found no changes in the expression of any of the mGluRs studied. These results sug-
gest that alterations of mGluR1a and mGluR2/3 expression in the PFC may contribute
to the pathophysiology of schizophrenia, and support targeting these receptors for the
generation of novel treatment modalities for this disabling illness. Synapse 57:123–
131, 2005. VC 2005 Wiley-Liss, Inc.
KEY WORDS mGluR; Western blot; postmortem brain; human; neuroanatomy;
immunoreactivity
INTRODUCTION
Converging lines of evidence implicate glutamater-
gic abnormalities in schizophrenia (Clinton et al.,
2003; Clinton and Meador-Woodruff, 2003; Goff and
Coyle, 2001; Kegeles et al., 2000; Meador-Woodruff
et al., 2001b, 2003; Meador-Woodruff and Healy,
2000; Mueller et al., 2004; Mueller and Meador-Wood-
ruff, 2004; Theberge et al., 2002). While pharmacolog-
ical data suggest NMDA receptor dysfunction, other
studies and theoretical considerations indicate that
other receptors associated with glutamatergic trans-
mission may be abnormal in this illness. One such
family of molecules, the metabotropic glutamate
receptors (mGluRs), are G-protein-linked receptors
that facilitate myriad synaptic functions, including
regulation of synaptic glutamate levels and long-term
potentiation. Given these critical roles in glutamate
neurotransmission and evidence implicating glutama-
tergic dysfunction in schizophrenia, we investigated
mGluR expression in schizophrenia.
Eight mGluRs have been identified and grouped
into three categories based on sequence homology,
second messenger coupling, and agonist specificity
(Nakanishi, 1992, 1994; Nakanishi et al., 1998; Pin
and Duvoisin, 1995). mGluR1 (mGluR1a–d), mGluR4
(a and b), and mGluR5 (a and b) may be alternatively
spliced at the c-terminus (Conn and Pin, 1997). Group
I mGluRs (mGluR1 and mGluR5) are positively
coupled to phosphoinositide hydrolysis via phospholi-
pase C activation and typically increase cellular excit-
ability by increasing depolarization (Hubert et al.,
2001). Group II (mGluR2 and 3) and group III
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mGluRs (mGluR 4, 6, 7, and 8) are negatively coupled
to adenylate cyclase and their activation results in
reduced neurotransmitter release (Hubert et al.,
2001). Group II and group III mGluRs are differenti-
ated based on their responses to the agonists trans-1-
aminocyclopentane-1, 3-dicarboxylate and L-2-amino-
4-phosphonobutyrate (Mateos et al., 2000).
mGluRs are found throughout the brain, including
unique patterns of expression in the prefrontal cortex,
thalamus, and striatum. Single cell polymerase chain
reaction (PCR) studies in rat have found that group I
mGluRs are the most abundantly expressed of the
mGluRs in both pyramidal neurons and interneurons
in neocortex (Cauli et al., 2000). mGluR2 and
mGluR3 share very high sequence homology such
that antibodies raised for one typically crossreact
with the other. Presynaptic mGluR2 and mGluR3
(mGluR2/3) immunoreactivity has been detected at
asymmetric synapses in all cortical layers (Muly
et al., 2003; Petralia et al., 1996). In the striatum,
mGluR1a and mGluR5 are expressed by different
subpopulations of interneurons and projection neu-
rons (Tallaksen-Greene et al., 1998). The group III
mGluRs, mGluR4 and mGluR7, are expressed at
asymmetric synapses in the striatum (Bradley et al.,
1999a,b; Kosinski et al., 1999).
Several studies have examined mGluR mRNA or
protein expression in schizophrenia. In general, few
significant changes in mGluR gene expression in
schizophrenia have been reported. mGluR5 mRNA
was increased in the pyramidal cell layers of Brod-
mann area 11, but decreased in the parahippocampal
gyrus in a different study (Crook et al., 2002;
Ohnuma et al., 1998, 2000). In contrast, more robust
findings have emerged from linkage studies suggest-
ing the involvement of both mGluR3 and mGluR5 in
schizophrenia (Chen et al., 2005; Devon et al., 2001;
Egan et al., 2004; Fujii et al., 2003). Other genetic
studies have also suggested the involvement of RGS-
4, which regulates the activity of mGluR1 and
mGluR5, in the pathophysiology of this illness (Chow-
dari et al., 2002).
The prefrontal cortex (PFC) has emerged as the
dominant site of abnormal brain function in schizo-
phrenia based on several lines of evidence as
reviewed elsewhere (Bunney and Bunney, 2000; Wein-
berger et al., 2001). Similarly, different regions of the
neostriatum, including the caudate nucleus, putamen,
and nucleus accumbens, are abnormal in schizophre-
nia based on morphological, physiological, and neuro-
psychological findings (Braff and Geyer, 1990; Dean
and Hussain, 2001; Healy et al., 1998; Hsiao et al.,
2003; McCullumsmith and Meador-Woodruff, 2002;
Meador-Woodruff et al., 1996, 2001b; Noga et al.,
1997). The PFC and the striatum have dense gluta-
matergic innervations, including cortical glutamater-
gic projections to the striatum, and the mGluRs have
a central role in the regulation of glutamate transmis-
sion in these regions. Based on the critical role of
mGluRs in glutamatergic neurotransmission and evi-
dence implicating the PFC and striatum in schizo-
phrenia, we examined expression of mGluR1a, 2/3,
4a, and 5 in Brodmann areas (BA) 9, 11, 32, and 46 of
the PFC, and in the caudate, putamen, and nucleus
accumbens in subjects with schizophrenia and a com-
parison group.
MATERIALS AND METHODS
Acquisition and processing of the postmortem
brain tissue
The subjects were from the Mount Sinai Medical
Center and Bronx Veterans Administration Medical
Center. Subjects were diagnosed with schizophrenia if
the following criteria were fulfilled: 1) the presence of
schizophrenic symptoms could be documented before
age 40; 2) the medical records contained evidence of
psychotic symptoms and at least 10 years of psychiatric
hospitalization with a diagnosis of schizophrenia; 3)
the DSM-III-R diagnosis of schizophrenia was agreed
upon by two experienced clinicians; 4) the neuro-
pathologic examination did not reveal Alzheimer’s
disease or other neurodegenerative disorders. Charac-
teristics of the subjects are summarized in Table I.
Brains obtained at autopsy were prepared by slicing
one hemisphere into 0.5–0.8-cm coronal slabs which
were snap-frozen in liquid nitrogen-cooled isopentane.
Brodmann areas were defined by sulcogyral position
and –808C storage time ranged from 2–3 years.
Antibodies
Commercially available antibodies used in these
studies are listed in Table II. These antibodies have
previously been used for Western blot experiments
and were demonstrated to not crossreact with other
mGluRs (Aronica et al., 2000, 2003; Gill et al., 1999).
Western blot analysis
We have previously utilized sections from the tissue
blocks for this cohort in several in situ hybridization
and receptor binding studies (Healy et al., 1998; Mea-
dor-Woodruff et al., 1996, 1997, 2001a). After section-
ing for the aforementioned studies, the tissue remain-
ing on the blocks was stored at –808 C.
Prior to dissection of tissue from the blocks for
Western blot analysis, we Nissl-stained the last sec-
tion to permit further identification and confirmation
of the anatomical region harvested for each subject.
For the nucleus accumbens, putamen, caudate, and
BAs, 9 (superior frontal gyrus), 11 (orbital gyrus,
gyrus rectus), 32/24 (cingulate gyrus), and 46 (dorso-
lateral prefrontal cortex), 1 cm3 of tissue was dis-
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sected, weighed, and homogenized (10% W/V) in
50 mM Tris-HCl (pH 7.0) for 30 sec with a polytron
homogenizer. The total protein concentration was
determined by the Bradford method (Bradford, 1976).
The homogenates were stored in 0.5-ml aliquots at
–808C. For each antibody, gels were run and the blots
were probed at the same time under identical condi-
tions. The samples were prepared by combining
homogenate with sample buffer (62.5 mM Tris-HCl,
20% glycerol, 2% sodium dodecyl sulfate, 5% b-mer-
captoethanol, pH 6.8) and heating at 958C for 4 min.
Using the Mini-Protean II Slab Cell SDS PAGE sys-
tem (Bio-Rad, Hercules, CA), 7% polyacrylamide gels
were prepared (7% acrylamide/bisacryamide, 10%
SDS, 12.5 ml TEMED/ 25 ml, 10% ammonium persul-
fate in 1.5 M Tris-HCl, pH 8.8) and 40 mg of protein
homogenate was loaded in duplicate and run in SDS/
Tris/glycine buffer (25 mM Tris-HCl, 192 mM glycine,
0.1% SDS, pH 8.3) at 100 mV for about 1 h. Following
transblotting to nitrocellulose membrane in Tris-gly-
cine buffer (25 mM Tris, 192 mM glycine, pH 8.3),
blots were blocked with 3% milk (in case of anti-
mGluR4a, 5% milk) in phosphate-buffered saline
(PBS) and agitated at 48C overnight with rabbit poly-
clonal antibodies (1 mg/ml primary antibody in 3%
milk in PBS) (Table II).
Next, blots were washed in distilled water and
incubated with secondary antibody (horseradish per-
oxidase coupled donkey antirabbit immunoglobulin;
Amersham, Piscataway, NJ) for 1.5 h on a shaker at
room temperature. After four additional washes,
enhanced chemiluminescence (ECL; Amersham) was
used for detection of immunoreactivity. Blots were
saturated with the ECL reagent, covered in Saran
wrap, and exposed to ECL film (Amersham). The
films were developed and digitally captured with a
TABLE I. Subject characteristics
Diagnosis Age (years) Gender Rx PMI (minutes) pH Cause of death
CTL 88 M N 285 5.9 Cardiac
CTL 86 F N 280 6.5 Unknown
CTL 70 M N 482 6.0 Pulmonary hypertension
CTL 55 M N 600 5.7 Cancer
CTL 79 F N 181 5.5 Cardiopulmonary failure
CTL 96 F N 195 6.7 Cardiopulmonary failure
CTL 90 F N 250 6.0 Cardiopulmonary failure
CTL 74 F N 180 6.0 Cardiopulmonary failure
CTL 98 F N 85 6.6 Cardiopulmonary failure
77 6 17 3M/6F 282 6 161 6.1 6 0.4
SCZ 54 M Y 490 6.0 Acute myelocytic leukemia
SCZ 61 M Y 212 6.5 Cardiopulmonary failure
SCZ 84 M Y 372 6.5 Cardiopulmonary failure
SCZ 69 M Y 270 6.4 Cardiac infarction, renal
failure
SCZ 76 F Y 510 6.1 Cardiopulmonary failure,
cancer
SCZ 75 F Y 334 6.8 Cardiopulmonary failure
SCZ 63 M Y 372 5.9 Cardiopulmonary failure
SCZ 69 F Y 820 6.2 Cardiopulmonary failure
SCZ 87 M Y 670 6.5 Cardiopulmonary failure
SCZ 68 M Y 335 6.8 Cardiopulmonary failure
SCZ 64 F Y 392 6.6 Cardiopulmonary failure
SCZ 86 F Y 415 5.8 Respiratory, renal failure
SCZ 86 F N 330 6.2 Cardiac, pneumonia
SCZ 72 M N 1235 6.6 Cardiopulmonary failure
SCZ 65 F N 350 5.9 Cardiopulmonary failure
SCZ 79 F N 1225 7.1 Cardiopulmonary failure,
cancer
72 6 10 8M/8F 520 6 314 6.3 6 0.4
Abbreviations: control (CTL), schizophrenia (SCZ), postmortem interval (PMI), female (F), male (M), no antipsychotic
treatment within 6 weeks of death (N), antipsychotic treatment within six weeks of death (Y). Data presented as
means 6 standard deviation.


















*100% homology with the human sequence.
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Macintosh-based CCD imaging system with NIH
Image 1.6. Gray scale values were obtained for pro-
tein bands detected by ECL at the expected molecular
weight, membrane background was subtracted, and
the adjusted gray scale values from duplicate samples
in adjacent lanes were averaged and converted to
optical density (O.D.).
Stastistical analysis
Statistical analysis was performed with Statistica
(StatSoft, Tulsa, OK). The gender distribution
between the two groups did not significantly differ
(v2 ¼ 2.2, P > 0.05). In addition, there were no differ-
ences in pH, age, or postmortem interval (PMI)
between the schizophrenic and control groups. We
used regression analysis to assess the potential con-
founding effects of following variables: age at death,
PMI, and tissue pH. When significant correlations
were detected we used multivariate analysis of cova-
riance (ANCOVA) to account for effects of covariates
on mGluR expression. Otherwise, we used multivari-
ate analysis of variance (ANOVA), followed by Tukey’s
HSD, when appropriate. We performed eight primary
analyses, using subregion and diagnosis as independ-
ent variables and mGluR protein expression as the
dependent variable. For all tests a ¼ 0.05.
RESULTS
We detected mGluR1a, mGluR2/3, mGluR4a, and
mGluR5 immunoreactivity in BA 9, 11, 32, and 46 as
well as caudate, putamen, and nucleus accumbens.
Representative Western blots for BA 9 and the
nucleus accumbens are shown in Figure 1.
Group I mGluR protein expression
Prefrontal cortex
We did not find associations between age, PMI, or
pH and mGluR1a immunoreactivity. We detected a
main effect for diagnosis (F(1,75) ¼ 4.13, P < 0.04)
and region (F(3,75)¼ 29.8, P < 0.01), but not a diag-
nosis by region interaction (F(3,75) ¼ 0.64, P > 0.5)
for increased mGluR1a expression (Fig. 2A). Post-hoc
analyses showed that mGluR1a expression was signif-
icantly lower in BA46 than in BA11 (P < 0.01), BA32
(P < 0.01), and BA9 (P < 0.02).
We did not find an association between age or pH
and mGluR5 expression (Fig. 2B). PMI was positively
correlated with mGluR5 levels in the PFC (r ¼ 0.52 ,
P < 0.05). ANCOVA with PMI as a covariate showed
a main effect for region (F(3,74) ¼ 19.33, P < 0.01),
but not for diagnosis (F(1,74) ¼ 1.07, P > 0.30) or
diagnosis by region interaction (F(3,74) ¼ 0.22, P >
0.88) for mGluR5 expression. mGluR5 expression was
significantly lower in BA32 than in BA9 (P < 0.02)
and BA46 (P < 0.01).
Striatum
We found a negative correlation between PMI and
mGluR1a levels in the striatum (r ¼ 0.55, P < 0.01).
We did not find associations between age or pH and
mGluR1a levels in striatum. We found a main effect
for region (F(1,54) ¼ 11.83 P < 0.01) but not for diag-
nosis (F(1,54) ¼ 1.504, P > 0.22) or diagnosis by
region interaction mGluR1a (F(2,54) ¼ 1.073 P >
0.34) for striatal expression of mGluR1a with PMI as
a covariate (Fig. 2C). Post-hoc tests showed that the
expression levels of mGluR1a are significantly lower
in the putamen compared to the caudate nucleus (P <
0.01) and nucleus accumbens (P < 0.01).
We did not find associations between age, PMI, or
pH and striatal levels of mGluR5. We found a main
effect for region (F(2,53) ¼ 8.40 P < 0.01) but not for
diagnosis (F(1,53) ¼ 0.69, P > 0.41) or region by diag-
nosis interaction (F(2,53) ¼ 0.016 P > 0.98) for
mGluR5 expression (Fig. 2D). The expression of
mGluR5 was significantly higher in putamen than in
caudate nucleus (P < 0.01) and nucleus accumbens
(P < 0.01).
Group II mGluR protein expression
Prefrontal cortex
We did not find an association between age, pH,
or PMI and mGluR2/3 protein expression. We found
Fig. 1. Representative Western blot analysis of mGluR1a, mGluR2/3, mGluR4a, and mGluR5 pro-
tein in the prefrontal cortex (BA9) and striatum (nucleus accumbens). Data shown are from three
different subjects run in duplicate.
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main effects for diagnosis (F(1,74) ¼ 4.5, P < 0.037)
and region (F(3,74) ¼ 14.7, P < 0.01) but not for
diagnosis by region interaction (F(3,74) ¼ 1.22, P >
0.30) for increased mGluR2/3 expression in PFC
(Fig. 3A). Post-hoc tests showed that mGluR2/3
expression in BA 46 was significantly lower than
in BA9 (P < 0.01), BA 32 (P < 0.01), and BA 11
(P < 0.01).
Striatum
We found no associations between age, pH, or PMI
and mGluR2/3 levels in the striatum. We found a
main effect for region (F(1,52) ¼ 13.95, P < 0.01) but
not diagnosis (F(1,52) ¼ 2.59, P > 0.11) or diagnosis
by region interaction (F(1,52) ¼ 0.69, P > 0.50)
(Fig. 3B). Post-hoc analysis showed that mGluR2/3
expression is significantly higher in nucleus accum-
Fig. 3. Western blot analysis of mGluR2/3 protein expression in the prefrontal cortex (A) and
striatum (B) in schizophrenia and a control group. mGluR2/3 immunoreactivity was significantly
increased in subjects with schizophrenia (SCZ) compared to controls (CTL) across Brodmann areas
(BA) 9, 11, 32, and 46.
Fig. 2. Western blot analysis of mGluR1a (A,C) and mGluR5 (B,D) protein expression in the pre-
frontal cortex (A,B) and striatum (C,D) in schizophrenia and a comparison group. mGluR1a immunore-
activity was significantly increased in subjects with schizophrenia (SCZ) compared to controls (CTL)
across Brodmann areas (BA) 9, 11, 32, and 46.
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bens than caudate nucleus (P < 0.01) and putamen
(P < 0.01).
Group III mGluR protein expression
Prefrontal cortex
We found an association between age and mGluR4a
expression in the PFC (r ¼ 0.56, P < 0.05). Using age
as a covariate, we found a main effect for region
(F(1,72) ¼ 29.6, P < 0.01) but not diagnosis (F(1,72) ¼
0.054, P > 0.81) or region by diagnosis interaction
(F(3,72) ¼ 0.450, P > 0.71) (Fig. 4A). Post-hoc tests
showed that mGluR4a expression was significantly
higher in BA32 than in BA9 (P < 0.01), BA11 (P <
0.01), and BA46 (P < 0.01).
Striatum
We did not find associations between age, pH, or
PMI and striatal mGluR4a levels. We found a main
effect for region (F(2,50) ¼ 9.65, P < 0.01) but not for
diagnosis (F(1,50) ¼ 0.37, P > 0.54) or region by diag-
nosis interaction (F(2,50) ¼ 0.28, P > 0.75) for striatal
mGluR4a expression (Fig. 4B). Post-hoc analysis
showed significantly higher expression of mGluR4a in
the putamen as compared to caudate nucleus (P <
0.01) and nucleus accumbens (P < 0.01).
Summary of results
We found increased expression of mGluR1a and
mGluR2/3, but not mGluR4a or mGluR5, in PFC in
schizophrenia (Figs. 2, 3). In contrast to the findings
in the prefrontal cortex, we did not find changes in
striatal expression of any of the mGluRs we examined
in schizophrenia.
DISCUSSION
We found significant increases in mGluR1a and
mGluR2/3 protein in several areas of the PFC in
schizophrenia (Figs. 2A, 3A). These findings are con-
sistent with a previous report of increased group I
mGluR expression in this illness (Ohnuma et al.,
1998). Transcripts for mGluR5, but not mGluR3, were
increased in neurons in BA11 in schizophrenia. Other
studies have not detected changes in mGluR expres-
sion. mGluR5 mRNA was decreased in schizophrenia
in the parahippocampal gyrus, while another group
did not find any changes in group II mGluR protein
expression in BA46 in this illness (Crook et al., 2002;
Ohnuma et al., 1998, 2000). While the balance of
these studies suggest that it is unclear if there are
abnormalities of mGluR expression in the PFC in
schizophrenia, our data support the hypothesis that
mGluR expression in the PFC is abnormal in this ill-
ness.
In contrast to the PFC, mGluR expression has not
previously been examined in the striatum in schizo-
phrenia. We did not detect any changes in mGluR
protein expression in this region. However, there are
several studies that suggest abnormal glutamate
transmission in the striatum in schizophrenia, includ-
ing findings of decreased D-aspartate (a marker for
high-affinity glutamate uptake sites) in the putamen,
increased AMPA receptor binding in caudate nucleus,
increased NMDA receptor density in putamen, and
decreased excitatory amino acid transporter 3 tran-
script expression in the striatum (Aparicio-Legarza
et al., 1998; McCullumsmith and Meador-Woodruff,
2002; Noga et al., 1997; Simpson et al., 1998). Thus,
while there are some abnormalities of proteins associ-
ated with glutamate transmission in the striatum in
schizophrenia, our findings suggest they do not
include changes in mGluR expression.
The cellular expression pattern and specific func-
tions attributed to different groups of mGluRs
provide a basis for interpreting our results of in-
creased mGluR1a and mGluR2/3 protein expression
in schizophrenia. Previous studies have demonstrated
mGluR1a labeling in the spines and dendrites of pyr-
amidal cells and interneurons, indicating a post-
Fig. 4. Western blot analysis of mGluR4a protein expression in the prefrontal cortex (A) and stria-
tum (B) in schizophrenia and a control group. Schizophrenia (SCZ), controls (CTL), Brodmann area
(BA).
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synaptic localization of mGluR1a in the PFC (Muly
et al., 2003). Increased mGluR1a protein expression
in schizophrenia may be attributed to pyramidal cells,
interneurons, or both, and there are data implicating
alterations in both of these cell types in the PFC in
this illness. While the techniques used in this study
do not permit us to attribute increases in mGluR1a
expression to one of these populations of cells, our
findings are consistent with previous reports of abnor-
malities of cortical neurons in schizophrenia, as well
as the functional roles of mGluRs in the glutamate
synapse. Activation of postsynaptic mGluR1a may
depolarize cell membranes, increasing the excitability
of neurons. Localized postsynaptic depolarization by
mGluRs contributes to removal of the Mgþþ block of
NMDA receptors, promoting NMDA receptor activa-
tion. Interestingly, mGluR1a is associated with
NMDA receptors in the postsynaptic density (PSD),
and several molecules have been identified that pro-
mote colocalization of these receptors in the PSD
(Husi et al., 2000). Since the glutamate hypothesis of
schizophrenia includes NMDA receptor hypofunction
as a primary pathophysiological lesion, an increase in
mGluR1a could be interpreted as a compensatory
response to diminished NMDA receptor function in
this illness.
In contrast to postsynaptic expression of mGluR1a,
mGluR2/3 immunostaining is predominately presy-
naptic (Petralia et al., 1996). An increase in presynap-
tic expression of mGluR2/3 in schizophrenia may lead
to a decrease in glutamate release and/or an increase
in glutamate reuptake, since mGluR2 and mGluR3
regulate these activities. A decrease in synaptic gluta-
mate levels is consistent with both a decrease in
NMDA receptor activation in the PFC and previous
findings of hypofrontality in schizophrenia.
We found increases in both mGluR1a and mGluR2/
3 in the PFC in schizophrenia. Since mGluR1a and
mGluR2/3 may enhance and attenuate synaptic trans-
mission, respectively, these findings argue against the
conclusion that mGluR modulation of synaptic trans-
mission is regulated in a simplistic manner (Hubert
et al., 2001). However, there are several possible
explanations that reconcile concomitant increases in
protein expression for these receptors. Changes in
mGluR1a and mGluR2/3 protein expression may
occur in different types of synapses. For example, if
increases in mGluR1a were limited to synapses com-
prised of glutamatergic synapses on postsynaptic
GABAergic neurons, an increase in mGluR-mediated
NMDA receptor activity would increase intrinsic
inhibitory transmission in the PFC. Such an altera-
tion would be consistent with an increase in pre-
synaptic mGluR2/3 protein expression, which may
also decrease excitatory neurotransmission by
decreasing release or increasing reuptake of gluta-
mate. On the other hand, changes in mGluR1a and
mGluR2/3 may be present in the same synapses. In
this instance, an abnormality of the normally tightly
regulated coordination of synaptic transmission might
result in disparate compensatory responses, where
regulation of activities such as glutamate release by
presynaptic neurons or glutamate reuptake by astro-
cytes are not properly coupled to regulation of the
postsynaptic neuron.
There are several potential limitations of this study.
We performed a secondary analysis of mGluR expres-
sion in unmedicated vs. medicated subjects with
schizophrenia, and did not detect any significant
changes in mGluR expression between these groups.
However, since only four out of 12 of our subjects in
the group with schizophrenia were medication free
for at least 6 weeks at the time of death, this secon-
dary analysis is underpowered to detect changes in
mGluR expression. In one previous report there were
no changes in mGluR2, mGluR3, mGluR5, or mGluR7
transcript expression in rat frontal cortex following
21 days of treatment with haloperidol (1 mg/kg) (Tas-
cedda et al., 2001). Although these results suggest
that our findings of increased mGluR1 and mGluR2/3
protein expression in the PFC in schizophrenia may
not be the result of a medication effect, the older
schizophrenics in our study have higher lifetime expo-
sures to neuroleptic medications, compared to sub-
jects in younger cohorts, possibly amplifying effects
attributable to antipsychotic medications. Thus, since
the effects of chronic antipsychotic treatment on
mGluR expression are not known, the possibility
remains that our findings of increased group I and
group II mGluR expression in the PFC in schizophre-
nia are secondary to antipsychotic treatment.
Another concern is that we studied aged individuals,
a potential limitation of this collection as compared to
those studied from other brain banks. Although the
current study is significant for increased expression of
mGluR2/3 and mGluR1a in an aged schizophrenic pop-
ulation, such findings may not be present in a younger
group of patients, suggesting that the changes we have
detected by and large represent the later stages of this
illness. In fact, the study by Crook et al. (2002) that
did not detect any changes in cellular localization or
laminar distribution of mGluR2/3 protein in BA46 was
done in a younger group of patients. However, the
advanced age of our subjects may be a strength of this
cohort; the subjects are free from comorbid traits such
as suicide and substance abuse that confound many
younger cohorts, have a predominance of negative
symptomatology and cognitive impairment commonly
found in the later stages of this illness, thus providing
an enriched, more homogenous sample, and are rigor-
ously characterized antemortem providing a level of
reliability of diagnostic and demographic variables
that are difficult to achieve in this field (Perl et al.,
2000).
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Only nine control subjects were included in this
cohort, potentially limiting the power of our study to
detect significant changes. In addition, since we
measured mGluR protein expression in brain homoge-
nates, our findings only indicate whether or not there
was a change in total mGluR protein expression and
do not specify the type of cell or synapse where
mGluR expression is altered. Finally, changes in pro-
tein expression do not necessarily indicate a change
in receptor function. There may also be changes in
mGluR surface expression, localization to the proper
region of the plasma membrane, or linkage to intra-
cellular signaling machinery.
CONCLUSIONS
Our findings of increased expression of mGluR1a
and mGluR2/3 protein in the PFC suggest that
mGluR activity may be increased in schizophrenia.
Such an alteration in mGluR activity might alter syn-
aptic plasticity, since the affected mGluR isoforms
modulate several activities critical for normal synap-
tic transmission, including postsynaptic membrane
excitability, glutamate release, and glutamate reup-
take. Our data suggest that the glutamate hypothesis
of schizophrenia includes abnormalities of mGluR
expression and support modulation of mGluR activity
as a target for pharmacological intervention in this
devastating illness.
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Knèopfel T, Grandes P. 2000. Immunolocalization of the mGluR1b
splice variant of the metabotropic glutamate receptor 1 at parallel
fiber-Purkinje cell synapses in the rat cerebellar cortex. J Neuro-
chem 74:1301–1309.
McCullumsmith RE, Meador-Woodruff JH. 2002. Striatal excitatory
amino acid transporter transcript expression in schizophrenia,
bipolar disorder, and major depressive disorder. Neuropsychophar-
macology 26:368–375.
Meador-Woodruff JH, Healy DJ. 2000. Glutamate receptor expres-
sion in schizophrenic brain. Brain Res Brain Res Rev 31:288–294.
Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL,
Watson SJ. 1996. Dopamine receptor mRNA expression in human
striatum and neocortex. Neuropsychopharmacology 15:17–29.
Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M,
Davis KL, Watson SJ. 1997. Dopamine receptor transcript expres-
130 D.S. GUPTA ET AL.
sion in striatum and prefrontal and occipital cortex. Focal abnor-
malities in orbitofrontal cortex in schizophrenia. Arch Gen Psy-
chiatry 54:1089–1095.
Meador-Woodruff JH, Davis KL, Haroutunian V, Mental Health
Research I. 2001a. Abnormal kainate receptor expression in prefron-
tal cortex in schizophrenia. Neuropsychopharmacology 24:545–552.
Meador-Woodruff JH, Hogg AJ, Smith RE. 2001b. Striatal ionotropic
glutamate receptor expression in schizophrenia, bipolar disorder,
and major depressive disorder. Brain Res Bull 55:631–640.
Meador-Woodruff JH, Clinton SM, Beneyto M, McCullumsmith RE.
2003. Molecular abnormalities of the glutamate synapse in the
thalamus in schizophrenia. Ann N Y Acad Sci 1003:75–93.
Mueller HT, Meador-Woodruff JH. 2004. NR3A NMDA receptor sub-
unit mRNA expression in schizophrenia, depression and bipolar
disorder. Schizophrenia Res 71:361–370.
Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH. 2004.
Expression of the ionotropic glutamate receptor subunits and
NMDA receptor-associated intracellular proteins in the substantia
nigra in schizophrenia. Brain Res Mol Brain Res 121:60–69.
Muly EC, Maddox M, Smith Y. 2003. Distribution of mGluR1alpha
and mGluR5 immunolabeling in primate prefrontal cortex. J
Comp Neurol 467:521–535.
Nakanishi S. 1992. Molecular diversity of glutamate receptors and
implications for brain function. Science 258:597–603.
Nakanishi S. 1994. Metabotropic glutamate receptors: synaptic
transmission, modulation, and plasticity. Neuron 13:1031–1037.
Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe
D, Yamaguchi S, Kawabata S, Okada M. 1998. Glutamate recep-
tors: brain function and signal transduction. Brain Res Brain Res
Rev 26:230–235.
Noga JT, Hyde TM, Herman MM, Spurney CF, Bigelow LB, Wein-
berger DR, Kleinman JE. 1997. Glutamate receptors in the post-
mortem striatum of schizophrenic, suicide, and control brains.
Synapse 27:168–176.
Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. 1998.
Expression of the human excitatory amino acid transporter 2 and
metabotropic glutamate receptors 3 and 5 in the prefrontal cortex
from normal individuals and patients with schizophrenia. Brain
Res Mol Brain Res 56:207–217.
Ohnuma T, Tessler S, Arai H, Faull RL, McKenna PJ, Emson PC.
2000. Gene expression of metabotropic glutamate receptor 5 and
excitatory amino acid transporter 2 in the schizophrenic hippo-
campus. Brain Res Mol Brain Res 85:24–31.
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